TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging~  * Age ≥ 25 years and ≤ 50 years~ * Pre-operative hemoglobin \>10 g/dl~ * Ability to understand and the willingness to sign a written informed consent.~ * Admissible medical/surgical history~ * Five or less symptomatic uterine myomas~ * symptomatic stage 3 to 6 fibroids, according to FIGO staging~Exclusion Criteria:~* • Post-menopausal women~  * Patients with known bleeding/clotting disorders~ * Patients with a history of gynecologic malignancy~ * Hypertension.~ * Cardiac and Pulmonary diseases.~ * History of allergic reactions attributed to carbetocin

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- carbetocin (Type: EXPERIMENTAL): 100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
- placebo (Type: PLACEBO_COMPARATOR): 10 cm syringe normal saline IV given just before skin incision of myomectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Antimicrobial Therapy Duration for Spondylodiscitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men or women more than 18 years~* proved bacterial spondylodiscitis due to pyogenic germ (no mycobacteria, no fungus or brucella), for which is decided a treatment antibiotic~* diagnosis is based on clinical,radiological and microbiological criteria~* women in age to procreate, use of an effective contraception with protected sexual relations and negative pregnancy test (b HCG).~Exclusion Criteria:~* infection with no bacteriological identification~* infection due to mycobacteria, brucella or fungus~* presence of material~* recurrence of spondylodiscitis~* Patient whose life expectation is 1-year-old subordinate~* pregnant or breast-feeding Woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): - group A : during 6 weeks after the inclusion
- 2 (Type: ACTIVE_COMPARATOR): -group B : during 12 weeks after the inclusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Histopathologically proven prostate adenocarcinoma.~* Rising prostate-specific antigen (PSA) (at least two consecutive rising PSAs) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).~  * Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation for biochemical recurrence after radical prostatectomy~    * PSA greater than or equal to 0.2 ng/mL measured more than 6 weeks after RP.~ * Post-radiation therapy -ASTRO-Phoenix consensus definition of biochemical recurrence after radiation therapy~    * Nadir + greater than or equal to 2 ng/mL rise in PSA~* Karnofsky performance status of \> 50 (or Eastern Cooperative Oncology Group (ECOG)/World Health Organization (WHO) equivalent).~* Age \>= 18.~* Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria~* Unable to lie flat, still or tolerate a PET scan.~* Concomitant investigational therapy.~* Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer.~* Contraindication to furosemide administration including prior allergy or adverse reaction to furosemide or sulfa drugs. (Note: This exclusion criteria can be removed if Furosemide is omitted as part of the PET imaging protocol if a second-generation scatter correction is available for the used PET device).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68 labeled PSMA-11 PET (Type: EXPERIMENTAL): PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-Patients with essential hypertension~Exclusion Criteria:~* Severe hypertension~* History or evidence of a secondary form of hypertension~* History of myocardial infarction. Other protocol-defined inclusion exclusion criteria also apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 18 years of age who are scheduled for unilateral cataract surgery~Exclusion Criteria:~* Have known hypersensitivity to bromfenac or to any component of the investigational product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bromfenac ophthalmic solution 0.09% (Type: EXPERIMENTAL): dosed 1 drop daily in study eye for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): dosed 1 drop daily in study eye for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent before any assessment was performed.~2. Randomized in study CFTY720DDE01 and received at least one dose of study drug (fingolimod) and completed the study.~3. Continuous intake of fingolimod after end of study CFTY720DDE01 with a maximum treatment interruption of 3 months in total before entering this study.~4. Parallel participation at study CFTY720DDE02 (Pangaea NIS) was allowed.~Exclusion criteriat:~1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.~2. Patients with onset of an acute relapse had to postpone their evaluation until deemed stable from relapse by treating physician, but at least for 1 month since end of relapse.~3. Patients that received immunomodulating or immunosuppressive MS treatments other than fingolimod since completion of study CFTY720DDE01 as for example: Natalizumab,Alemtuzumab, Dimethyl fumarate, Teriflunomide, intravenous Immunoglobulins,Mitoxantrone, Methotrexate, Azathioprine or experimental immunomodulating-immunosuppressive therapies.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fingolimod (Type: EXPERIMENTAL): Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) ≥30 to ≤45 kg/m²~* Diagnosis of eating disorder using The Questionnaire on Eating and Weight Patterns (QEWP-R) for diagnosing Eating Behaviors~Exclusion Criteria:~* History of surgical procedures for weight loss~* Treatment with anti-obesity drugs within 3 months prior to screening visit~* Presence or history of Diagnostic and Statistical Manual of Mental Disorders (4th edition)(DSM IV) bulimia or anorexia nervosa~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Men or women ≥50 years of age with type 2 diabetes mellitus on treatment with a glucose lowering medication since at least 6 months, and either documented coronary artery occlusive disease or previous revascularization of a coronary artery.~Key Exclusion Criteria:~History of myocardial infarction or any stroke; planned treatment with agents inhibiting blood clotting; planned use of ASA/Aspirin at doses above 150 mg daily; planned coronary, cerebrovascular, or peripheral arterial revascularization; patients with known bleeding disorders and patients who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin; history of intracranial bleeding at any time, or a history of bleeding from the gastrointestinal tract within the last 6 months or a major surgery within the last 30 days; patients with known severe liver disease or with kidney failure requiring dialysis

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 60 mg (Type: EXPERIMENTAL): Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
- Ticagrelor placebo (Type: PLACEBO_COMPARATOR): Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Breath Hold Abdominal MRI

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* undergoing abdominal MRI~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Breath hold Liver Acquisition with Volume Acquisition (LAVA) (Type: NO_INTERVENTION): Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
- Respiratory-triggered T1w DISCO LAVA (Type: ACTIVE_COMPARATOR): The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergo elective robot assisted radical prostatectomy, between 20 and 80 years with a American Society of Anesthesiologists physical status classification of I or II~Exclusion Criteria:~* Conduction abnormalities in preoperative EKG such as Atrioventricular block, sinus pause~* Glomerular filtration rate \<60ml/min/1.73m2~* Allergy to rocuronium, sugammadex, magnesium~* Medications that interfered with muscle activity~* Neuromuscular disease~* Hypermagnesemia

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Magnesium Sulfate group (Type: ACTIVE_COMPARATOR): magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
- Placebo group (Type: PLACEBO_COMPARATOR): Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Entocort for Children With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.~* Subject must be diagnosed with active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology.~* Subjects with mild to moderate Crohn's disease.~* All subjects must have a stool analysis negative for Clostridium difficile toxin, Yersinia enterolytica, Campylobacter jejuni, Salmonella, Shigella, within the 30 days prior to visit 1.~* All subjects must have had laboratory assessments within 7 days prior to visit 1.~* All subjects must weigh \>= 15 kg at time of enrollment~Exclusion Criteria:~* Subjects who have had any previous intestinal resection proximal to and including the ascending colon~* Subjects with evidence of severe active Crohn's disease and/or, stricturing and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications~* Subjects who do not have a negative stool analysis, within the 30 days prior to visit 1~* Subjects who have been screened/or enrolled in this study previously within the last 30 days~* Subjects with morning cortisol level \<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Entocort (Type: EXPERIMENTAL): Study Medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* If female, cannot be of reproductive potential~* Has been treated with an appropriate dose of statin for at least 6 weeks~* Coronary heart disease (CHD) or other atherosclerotic vascular disease with multiple risk factors (including diabetes, metabolic syndrome) and/or high LDL-C/low HDL-C, or needing to meet a specific LDL-C/HDL-C goal~Exclusion Criteria:~* Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor~* Homozygous familial hypercholesterolemia~* Severe chronic heart failure~* Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke within 3 months~* Uncontrolled hypertension~* Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins~* Active or chronic hepatobiliary, hepatic, or gall bladder disease~* History of mental instability, drug/alcohol abuse within the past five years or major psychiatric illness inadequately controlled and unstable~* History of ileal bypass, gastric bypass, or other significant condition associated with malabsorption~* Human immunodeficiency virus (HIV) positive~* History of malignancy ≤5 years~* Donated blood products or has had phlebotomy of \>300 mL within 8 weeks or intends to donate 250 mL of blood products or receive blood products within the projected duration of the study~* Currently taking medications that are potent inhibitors or inducers of cytochrome P450 3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's wort) or has discontinued treatment \<3 weeks prior~* Consumes more than 2 alcoholic drinks per day~* Currently participating or has participated in a study with an investigational compound or device within 3 months~* Receiving treatment with systemic corticosteroids or taking systemic anabolic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Anacetrapib (Type: EXPERIMENTAL): 100 mg tablet, oral, once daily for 24 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin as Adjuvant Therapy in Obese Knee Osteoarthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients have symptomatic and radiological evidence of OA in one or both knee joints.~* Age ≥ 45 years.~* Both obese male and female will be included (BMI ≥ 30 kg/m²).~Exclusion Criteria:~* Patients with inflammatory rheumatic diseases, crystal deposition arthritis or infection-induced OA.~* Patient with hypertension or diabetes mellitus.~* Patient with hepatic or renal impairment.~* Patients who have active peptic ulcer.~* Patients with positive malignancy.~* Steroid injection into the affected knee joint within 3 months of recruitment for the study.~* Pregnant or lactating female patients.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo group (Type: EXPERIMENTAL): Placebo tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.
- Metformin group (Type: EXPERIMENTAL): Metformin 500mg tablet twice daily + celecoxib 200mg capsule once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female 11-25 years old healthy subjects;~* who had received the primary immunization with a vaccine containing DT or Tdap antigens and a T, Td, or Tdap booster injection at least 5 years prior to study entry~Exclusion Criteria:~* previous ascertained or suspected disease caused by N. meningitidis~* previously been immunized with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* serious acute, chronic or progressive disease~* history of any anaphylaxis, serious vaccine reactions, or allergy to any vaccine component~* known or suspected impairment/alteration of immune function, either congenital or acquired

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Tdap + MenACWY-CRM (Type: EXPERIMENTAL): Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
- Tdap + saline (Type: EXPERIMENTAL): Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
- MenACWY-CRM + saline (Type: EXPERIMENTAL): Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete